regenxbio.com - RGNX Operating profit before amortization
REGENXBIO Inc. (RGNX) is a gene therapy leader featuring a unique NAV platform and a robust patent portfolio. The firm's environmental footprint remains minimal due to strict chemical controls. The GURU.Markets platform provides this chart, where absolute EBITDA dynamics show that the current level is around 0.00. However, financial stability depends on one-time partner payments until the full-scale launch of its own products.
%20Operating%20profit%20EBITDA&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_RGNX_-_REGENXBIO-Inc._-_Operating-profit-EBITDA "REGENXBIO Inc - RGNX Profit before payment of interest, taxes and amortization (period 11/23/2025 - 11/14/2026) | 👁️GURU.Markets👁️")
REGENXBIO - analytical breakdowns and key metrics (RGNX)
- share price and expert price forecast:
- issuer market value details:
- balance sheet net asset value indicators:
- business debt structure and liquidity details:
- net income and valuation multiples indicators:
RGNX - Net Income|Company Profit Forecast REGENXBIO Inc.|RGNX - Price to Earnings Ratio|Future Price to Earnings Multiple regenxbio.com|RGNX - PEG Multiple|Enterprise Value to EBITDA Multiple REGENXBIO|RGNX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months REGENXBIO|RGNX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months regenxbio.com|RGNX - Earnings growth in current year|Projected earnings per share growth rate for next year REGENXBIO Inc.
- sales revenue and business income indicators:
Summary company analytics:RGNX REGENXBIO Corp
For REGENXBIO Inc. (RGNX), whose gene therapy developments for blindness are entering the commercialization stage, the company's total operating profit reflects the actual cash flow from the core business before depreciation and interest. This indicator measures the efficiency of the operating cycle, allowing investors to assess the issuer's ability to cover expenses and service debt amid tight monetary policy.
Competitors of REGENXBIO Inc. (RGNX)
TEM: Operating profit before amortization|QGEN: Operating profit before deduction of amortization|IONS (ionispharma.com) - Operating profit before amortization|RGEN: Operating profit EBITDA|RNA (Avidity Biosciences Inc) - Profit before payment of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|GeneDx Corp (WGS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|BEAM - Profit before interest, taxes and amortization|Sarepta - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|Operating income before deduction of amortization Intellia Corp NTLA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Operating profit before amortization BLFS|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Operating profit before deduction of amortization SION (Sionna Pharma)|Operating income before deduction of amortization Prime Medicine Bio|Profit before payment of interest, taxes and amortization Taysha Gene Therapies TSHA|Income before deduction of interest, taxes and amortization QURE|MeiraGTx - Operating profit EBITDA|Operating profit before depreciation charges Solid Biosciences Inc (SLDB)|Ocugen Corp (OCGN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization PACB|Operating profit before deduction of amortization BNTC|Operating profit before amortization DSGN (designtx.com)|Operating profit EBITDA RCKT|4DMT - Operating profit before amortization|Profit before payment of interest, taxes and amortization Lexeo Therapeutics, Inc. LXEO|KRRO: Operating profit before amortization|Editas Medicine, Inc. - Operating profit EBITDA|SLN - Operating profit EBITDA|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Codexis - Income before deduction of interest, taxes and amortization|SGMO (Sangamo) - Operating profit EBITDA|Profit before interest, taxes and amortization Nautilus Biotechnology Inc NAUT|Operating profit EBITDA MGX|precisionbiosciences.com (DTIL) - Operating profit before depreciation charges|Operating profit EBITDA GBIO (Generation Bio)|Boundless Bio Inc. (BOLD) - Profit before interest, taxes and amortization|XCUR - Profit before payment of interest, taxes and amortization|IMNN (Imunon, Inc.) - Operating profit before amortization|PHIO (phiopharma.com) - Operating profit before deduction of amortization|Operating profit before amortization MBIO|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization BNGO|Operating profit EBITDA APDN|Operating income before deduction of amortization bluebird bio, Inc|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|omegatherapeutics.com (OMGA) - Profit before interest, taxes and amortization|OMIC: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RGLS (Regulus Therapeutics, Inc.)|SYRS: Operating profit EBITDA|TBIO - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before amortization UBX (unitybiotechnology.com)
